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INTRODUCTION
In 2012, breast and ovarian carcinoma accounted for 25.2 and 3.6% 
of worldwide 3.5 million cancer mortalities in women, respectively.1 
Especially aggressive forms of both tumor entities are character-
ized by some shared markers. Among these are the epithelial cell 
adhesion molecule (EpCAM) and the human epidermal growth fac-
tor receptor 2 (HER2/neu, or short HER2). Targeting of the tumor-
associated antigen HER2 by monoclonal antibodies has been a 
showcase for the development of targeted cancer medicine, which 
has first been authorized for the treatment of metastatic breast 
cancer.2 HER2, a receptor tyrosine kinase, is amplified in 15–30% 
of all breast3,4 and 9–32% of ovarian cancer patients.5 This cellular 
surface glycoprotein is an active “driver” oncogene, which has no 
known ligand, and its expression is clinically associated with poor 
prognosis. HER2-targeted therapies radically changed the way 
HER2-overexpressing tumors are treated, but a significant num-
ber of patients with recurrent, HER2-positive breast cancer do not 
respond to antibody therapy with or without chemotherapy (only 
25–50% response6). For ovarian carcinoma, numbers are even 
worse.7 Moreover, even responsive tumors eventually become resis-
tant. Reasons for the disappointing durability of response to HER2-
targeted therapies in advanced breast and ovarian carcinoma are 
complex, but can be partially explained by acquired resistance or a 
priori heterogeneity in tumor cell populations.8
High mutation rates and heterogeneity of tumor cells are a gen-
eral hallmark of cancer. Consequently, cell populations of advanced 
tumors are inherently diverse, also with regard to expressed mark-
ers, and can acquire escape mutations. Moreover, the stem cell 
theory of cancer proposes that among all cancerous cells within a 
tumor, a few act as stem cells that reproduce themselves and sus-
tain the tumor. In this view, it is especially these cancer stem cells 
(CSCs) that need to be targeted by a successful therapy in order to 
prevent the tumor from recurrence and becoming therapy resistant. 
Among the markers that identify potential CSCs9,10 is EpCAM.11–13 
It is often upregulated in epithelial tumors and is in general bet-
ter accessible for therapeutics here, since in the course of trans-
formation the polarity of EpCAM expression at tight junctions is 
lost and EpCAM molecules are homogenously distributed on the 
cancer cell surface.11 Interestingly, EpCAM is present at low levels 
in 48%, and overexpressed in approximately 35–42% of all breast 
tumor patients samples.14–16 In ovarian cancer, EpCAM-expression 
is upregulated even in 69% of all patients.17 Coexpression of HER2 
and EpCAM occurs in a significant number of breast cancer patients 
(13.2%) and further worsens prognosis.15 Thus, the treatment of 
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this particular subtype of carcinomas could be improved by com-
bination of HER2- and EpCAM-targeted therapies. The potential for 
tumor escape might be reduced when therapy is combined in one 
setting or even a single drug, an approach that can be realized by an 
oncolytic virus (OV) therapy.
OVs are novel cancer therapeutics and are intensively studied 
in preclinical and clinical studies. Most recently, an oncolytic her-
pesvirus named talimogene laherparepvec (Imlygic®) has received 
a positive recommendation for marketing authorization by the 
European Medicines Agency and the Federal Drug Agency for the 
treatment of melanoma.18 Notably, being replication competent 
viruses, OVs have a completely different mode of action than con-
ventional drugs.19,20 Due to the strongly lytic nature of its replica-
tion, measles virus (MV) appears as an ideal virus for use as OV with 
currently ongoing phase 1 trials for the treatment of six different 
tumor entities and a phase 2 study for multiple myeloma, which 
is recruiting patients.21 In general, MV is well tolerated and one 
patient with advanced multiple myeloma went into full remission 
after high-dose MV treatment, with flu-like symptoms during infu-
sion reported as most striking side effects.22 MV is the prototypic 
Morbillivirus and belongs to the Paramyxoviridae family. It is the 
causative agent of the measles, but live attenuated vaccine strains 
have been developed, which are among the most efficient and saf-
est vaccines known.23 MV vaccine strains use CD46 as entry recep-
tor24,25 in addition to the receptors used by pathogenic wildtype MV 
strains: SLAM on activated lymphocytes,26 or nectin-4 on epithelial 
cells lining the upper airways.27,28 CD46 is expressed on all human 
nucleated cells, but regularly found upregulated in certain tumors.29 
Accordingly, the tumor tropism of unmodified oncolytic MV derived 
from the Edmonston B vaccine strain has been correlated to CD46 
upregulation.30 However, this tropism is only relative, since the CD46 
is ubiquitously expressed on human cells.
On the virus surface, the viral glycoprotein hemagglutinin (H) is 
responsible for receptor attachment followed by triggering cell-
entry.31 MVs’ receptor usage can be altered by changing the binding 
specificity of H. This can be achieved by introducing four specific 
point mutations to ablate recognition of the native receptors32 and 
the genetic fusion of binding domains specific for the desired target 
receptor to the C-terminus of H. Usually, these have been single-
chain antibody fragments (scFv’s),33 natural receptor ligands34 or 
peptides.35 Thereby, MV tropism can be redirected to virtually any 
surface-exposed structure of choice.33 As an alternative binding 
domain, we recently developed a strategy36 using designed ankyrin 
repeat proteins (DARPins)37 to target tumor markers HER2 (ref. 38), 
EpCAM,39 or EGFR.40 The unique structural properties of DARPins 
enabled us to generate a bispecific MV using HER2 and/or EpCAM, 
as entry receptors.36 This virus was generated to address resistance 
development to mono-targeted therapies, but its qualities have 
only been partially characterized.36
Here, we aim to demonstrate the advantage of bispecific com-
pared to monospecific MVs and to optimize bispecific targeting 
by variation of the linker connecting both DARPins. All bispecific 
binding cassettes were demonstrated to bind to cells expressing 
HER2/neu or EpCAM, albeit to different extent. Linkers composed of 
nine proline residues or constituting two α-helical turns were identi-
fied to convey best fusion helper function in vitro. Viruses generated 
with these linkers as well as the prototype virus MV-Ec4-G3 (ref. 36) 
specifically infected cells via EpCAM or HER2. The viruses were found 
to be cytotoxic for two human carcinoma cell lines, while only one 
of these replicated the virus efficiently. Their oncolytic potential was 
shown in a disseminated ovarian cancer xenograft model in mice. 
Furthermore, the superior efficacy of bispecific over monospecific 
viruses was demonstrated in a cell culture model mimicking tumor 
heterogeneity, thus providing evidence for the versatility and effi-
cacy of such viruses for the therapy of advanced tumors.
ReSUlTS
Generation and analysis of bispecific targeting cassettes with 
optimized linkers
With the final aim to further enhance the oncolytic efficacy of MV 
by targeting two receptors of choice simultaneously, new bispecific 
binding cassettes were constructed by exchanging the linker pep-
tide connecting both DARPin domains (Figure 1a). The prototype 
virus encoded a glycine-serine linker ((G4S)2) between DARPins Ec4 
(binding EpCAM with a KD of 1.7 nmol/l) and G3 (binding HER2 with 
a KD of 0.09 nmol/l), genetically fused in tandem to the carboxy-ter-
minus of the mutated H protein.36 The same orientation of DARPins 
was used for testing different linkers, since for initial experiments 
using H-DARPin-linker-DARPin proteins with the prototypic ((G4S)2-
linker, the order of the DARPins did not matter with respect to fusion 
helper-activity (data not shown). Three different types of linkers 
were used: highly flexible glycine-serine linkers, more rigid poly-
proline linkers, and α-helical peptide linkers, which however can 
unfold. The linkers were varied in length covering between 5 (G4S) 
and 20 amino acids (aa) ((G4S)4), 9 aa (two full helical turns; αHelix2) 
and 17 aa (4 turns; αHelix4), or 9 and 18 aa of consecutive prolines. 
Furthermore, simple glycine-serine hinges (hi) were added to both 
ends of the rigid linkers to increase flexibility (Figure 1a).
The respective genes encoding the different H-DARPin-linker-
DARPin constructs were first cloned into pCG-1-derived expres-
sion plasmids. After transfection of these plasmids into 293T cells, 
all recombinant H-proteins were detected by immunoblot analysis 
(Figure  1b). All proteins revealed the expected shift in molecular 
weight, compared to unmodified H, of approximately 30 kDa, consis-
tent with the size of two connected DARPin units. No proteins with 
lower molecular weight became evident suggesting that there was 
no loss of the distal DARPin due to linker proteolysis. Furthermore, 
all proteins were successfully transported to the cell surface of trans-
fected 293T cells, as demonstrated by flow cytometry detecting the 
C-terminal surface-exposed His6-tag (Supplementary Figure S1).
To analyze functionality, i.e., fusion helper function, the H protein 
variants were transiently coexpressed with the MV fusion protein (F) 
in CHO-HER2-K6 or CHO-EpCAM #6 cells with defined receptor den-
sity.36 After binding its receptor, H initiates fusion of neighboring 
receptor-positive cells by triggering F to fuse the cell membranes, 
resulting in syncytia, i.e., multi-nucleated giant cells. Compared 
to the monospecific H-Ec4 or H-G3, the best fusion activity of the 
evaluated bispecific formats, indicated by formation of syncytia, 
was observed with medium sized linkers and regardless of their 
flexibility: (G4S)2 (10 aa), αHelix2 (9 aa), or Pro9 (9 aa). After bind-
ing to HER2, these proteins revealed almost completely conserved 
fusion helper function of between 80% (αHelix2 & Pro9) and 90% 
((G4S)2) as compared to monospecific H-G3 (Figure 1c). After binding 
to EpCAM, fusion helper function of bispecific constructs ranged 
from 40% ((G4S)2) to 60% (αHelix2 & Pro9) compared to H-Ec4. 
It should be noted that the anti-EpCAM DARPin is placed between 
the H-protein and the anti-HER2 DARPin, and may thus be more 
sterically constrained than the latter, shown in lower percentages 
compared to Ec4 itself. Longer linker peptides or additional hinge 
regions impaired function, as well as shorter linker peptides such 
as Gly-Ser (X/B; introduced XmaI/BstBI restriction sites) or a Gly4-Ser 
sequence. Hence, the linker variants αHelix2 and Pro9 were chosen 
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as alternatives to the prototype (G4S)2-linker for the generation of 
bispecific MVs.
For additional characterization, soluble versions of the bispecific 
binding domains were generated, which were fused to the N-terminus 
of human IgG1-Fc-portion. The Fc-part induces homo-dimerization 
and thus potentially results in bivalent binding of the DARPin-Fc com-
plexes. Recombinant DARPin-Fc proteins were expressed in 293T cells, 
purified (Supplementary Figure S2), and tested for binding to cell 
lines differing in HER2/neu or EpCAM surface expression (Table 1) by 
flow cytometry (Figure 1d, Supplementary Figure S3). Most interest-
ingly, Fc-dimerized (G4S)2- and αHelix2-linked proteins bound either 
HER2- or EpCAM-positive target cells with comparable efficacy also 
to monospecific DARPin-Fc-proteins. These comparably constructed 
proteins demonstrated unimpaired binding capacity of the DARPin 
units when fused to the Fc-portion. The Pro9-connected soluble bispe-
cific cassette bound both HER2 and EpCAM-expressing cells signifi-
cantly less efficiently indicating a negative impact of the Pro9 linker in 
the binding efficiencies of both DARPins, as discussed below.
Rescue and characterization of bispecific DARPin-MV with 
alternative linker peptides
After extension of the carboxy-terminal His6-tag by one extra his-
tidine to coincide with the rule-of-six,41 the targeted H-ORFs were 
cloned into the genome of attenuated Edmonston MV strain NSe 
(MVNSe) encoding eGFP as reporter protein (Figure 2a). All respective 
viruses were successfully rescued. These recombinant MVs were 
amplified on Vero-αHis cells and subsequently analyzed by immu-
noblot for H protein expression in infected cells (Figure 2b). Both 
MV-Ec4-Pro9-G3 and MV-Ec4-αHelix2-G3 showed expression of the 
recombinant H proteins with an approximately 30 kDa increase in 
molecular weight, as expected (Figure 2b).
In multi-step growth curves on Vero-αHis cells, similar maximal 
cell-associated titers around 1 × 105 TCID50/ml were reached 48 
hours after infection by all MVs (Figure 2c). As expected, the replica-
tion kinetics of the bispecific constructs closely reflected those seen 
Figure 1  Construction and function of different bispecific receptor-attachment proteins. (a) Schematic representation of the engineered H gene 
cassette. Restriction sites used for cloning are indicated. (b) Protein expression was analyzed in lysates of 293T cells transfected with plasmids encoding 
the indicated constructs 48 hours post-transfection with an antiserum (α-Hcyt) detecting the cytoplasmic tail of H, i.e. potentially also degradation 
products of H having (partially) lost the DARPin binding domain. β-actin served as loading control. (c) Fusion helper activity of all recombinant bispecific 
H variants was assayed by cotransfection of the respective pCG-H variants and pCG-F into single receptor-positive CHO-HER2-K6 (black) or CHO-EpCAM 
#6 (gray) cells and counting of nuclei from 25 individual syncytia. Relative fusion helper activities normalized by the amount of nuclei triggered by 
respective monospecific H proteins are depicted. Target receptor-independent background fusion activity of each monospecific construct is indicated 
by a black (Ec4) or gray (G3) horizontal line. Dashed black line indicates 100% fusion-helper activity of the respective monospecific H-DARPin proteins. 
(d) Binding of recombinant mono- and bispecific DARPin-Fc proteins (10 μmol/l) to CHO-HER2 and CHO-EpCAM61 cells analyzed by flow cytometry.
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Table 1 Surface density of targeted receptors as determined 
previously
Cell line HER2/cella EpCAM/cella CD46/cella
SK-OV-3 5.72 × 105 4.59 × 103 9.10 × 104
Caco-2 1.81 × 104 1.01 × 105 1.77 × 105
LN-308 4.76 × 103 -b 6.30 × 104
MCF-7 1.24 × 104 9.57 × 104 7.82 × 104
Data taken from ref. 36.
aNumber of respective HER2/neu, EpCAM, or CD46 molecules per cell. 
bBackground level as determined by isotype control.
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for monospecific MV-Ec4: Virus titers did not drop after  reaching 
their maximum, but stayed at a plateau until 6 days post infection 
(Figure 2c). Titers of all recombinant MV in the supernatant of 
infected  Vero-αHis revealed a similar pattern, but were reduced by 
half an order of magnitude and delayed by 24 hours (Figure 2d).
The receptor tropism of retargeted bispecific MVs was assessed 
by infecting a panel of transgenic CHO cell lines expressing either 
one of the native MV vaccine strain receptors (CD46, hSLAM, or 
nectin 4), or the targeted receptors (HER2 or EpCAM). As expected, 
neither CHO-K1 cells (not expressing any putative receptor) nor the 
CHO lines expressing one of the native MV receptors were infected 
by any retargeted virus, demonstrating successful detargeting from 
natural MV receptors. While monospecific MVs infected either CHO-
HER2 or CHO-EpCAM cells according to their respective specificity, 
bispecific MVs were able to infect both (Figure 3). Thus, target speci-
ficity was retained irrespective of the peptide linkers connecting 
both targeting domains of the bispecific MVs.
Cytotoxicity and replication of the recombinant MVs in vitro
Next, the oncolytic properties of the bispecific MVs were character-
ized using the human carcinoma cell lines SK-OV-3 (ovarian) and 
Caco-2 (colorectal), expressing different levels of HER2 or EpCAM 
(Table 1, Figure 4). First, cytotoxicity of the bispecific MVs was 
assessed by monitoring cell viability in MTT-assays in comparison to 
nontargeted or monospecific MV. Both tumor cell lines revealed a 
rapid decline in viability within the first 72 hours after infection with 
any of the viruses, except Caco-2 infected with MV-G3. This virus 
exhibited only moderate cytotoxicity in this setting (71.7% viability 
72 hours after infection, which declined to 28.7% 168 hours after 
infection). However, MV-G3 was more cytotoxic for SK-OV-3 cells 
than MV-Ec4 (27.7 versus 44.7% viability 72 hours after infection), 
which is likely explained by the 100-fold higher density of HER2 ver-
sus EpCAM in these cells. Interestingly, all bispecific viruses were at 
least as cytotoxic as MV-G3 on either cell line. In comparison to the 
nontargeted parental virus MVNSe, whose efficiency can be explained 
by the robust overexpression of its receptor CD46 on both cell lines 
(Table 1), MV-Ec4-Pro9-G3 even reached comparable cytotoxicity 
(15.3% versus 9.5% residual viability of infected SK-OV-3 72 after 
infection) (Figure 4a). In Caco-2 cells, residual viability dropped to 
almost undetectable levels 168 hours after infection with any bispe-
cific virus (Figure 4b). Thus, bispecific MVs demonstrated high onco-
lytic efficacy in vitro irrespective of the targeted receptor.
Surprisingly, analysis of viral replication on both target cell lines 
revealed a different picture. On SK-OV-3 cells, cell-associated virus 
Figure 2 Generation of bispecific viruses. (a) Schematic representation of bispecifically retargeted measles virus (MV) and its genome with cloning 
sites used for exchange of the H gene cassette. The same color code for proteins and their corresponding genes is used. Scheme73 modified with 
crystal structures from H, F74, and DARPins.75 (b) Immunoblot for detection of virus proteins. Lysates of infected Vero-αHis cells harvested 48 hours 
after infection (MOI = 0.1) were analyzed for indicated proteins. Protein content was normalized to MV-N and β-actin. (c) Multi-step growth analysis of 
parental MVNSe, monospecific-, bispecific prototype- (MV-Ec4-G3) and generated bispecific MV (MV-Ec4-αHelix2-G3 & MV-Ec4-Pro9-G3) on the producer 
cell line Vero-αHis after infection (MOI = 0.03) by analyzing cell associated (left panel) or released (right panel) virus titers.
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titers peaked 48 hours (MVNSe) or 72 hours after infection (all tar-
geted MVs). MVNSe and monospecific MV-Ec4 reached maximal 
cell-associated titers of 8.2 ± 2.7 × 103 TCID50/ml and 0.7 ± 1.0 × 10
4 
TCID50/ml, respectively. Ninety-six hours after infection, titers of 
both viruses stabilized at around 1 × 103 TCID50/ml. Peak titers of 
MV-G3 were reduced (2.7 ± 2.1 × 103 TCID50/ml) and dropped below 
the limit of detection (1 × 102 TCID50/ml) 96 hours after infection. 
Titers of the bispecific viruses were only slightly above the detec-
tion limit on SKOV-3 cells (Figure 4c), but within the range of the 
monospecific and parental viruses on Caco-2 cells (Figure 4d). 
The maximal cell-associated titers were between 3.0 ± 4.8 × 104 
TCID50/ml (MV-Ec4) and 5.5 ± 8.2 × 10
3 TCID50/ml (MV-G3). MVNSe 
and MV-Ec4 stabilized at about 10-fold lower levels during later 
time points, whereas MV-G3 and the bispecific MVs stayed at peak 
levels until 120 hours after infection (Figure 4d).
Interestingly, the time point for maximal titers varied between 
72 and 120 hours after infection. Thus, while the cytotoxicity of 
bispecific MVs was comparable with or even exceeded that of non-
targeted or monospecific viruses, maximal titers were significantly 
reduced in SK-OV-3, but not in Caco-2 or Vero-αHis cells. Titers of 
virus released into the supernatant revealed a similar pattern as 
those of cell-associated virus, but were roughly one order of magni-
tude lower, as expected for MV (Figure 4e,f ).
To exclude any effect on virus replication caused by sole bispecific 
binding to HER2 and EpCAM, we monitored virus titers after infec-
tion with nontargeted MVNse in the presence of bispecific DARPins 
potentially triggering inhibitory signaling via the targeted recep-
tors. For this purpose, DARPins were added to SK-OV-3 cells during 
infection with nontargeted MVNSe. No differences were found in 
peak virus titers 72 hours after infection irrespective of the binding 
proteins used for pretreatment of SK-OV-3 cells (Figure 4g).
Compared to the other cancer cell lines, SK-OV-3 cells express 
especially HER2/neu in very high amounts, and also EpCAM is 
detectable on this cell line.36 This high receptor expression may 
block virus replication, if receptor abundance and high-affinity 
interaction with recombinant H proteins would interfere, e.g., 
with protein processing in the endoplasmic reticulum. Although 
expression of recombinant H-DARPin-linker-DARPin proteins was 
comparable to that of monospecific H-DARPin (Figure 2b) and MV 
encoding the latter replicated well, we analyzed the abundance 
of recombinant H proteins on MV particles to reveal, if differen-
tial incorporation into virus particles during assembly may render 
bispecific MV vulnerable to slowed down replication in tumor 
cells with extraordinary receptor density. Indeed, when analyzing 
recombinant MVs purified from the supernatant of infected Vero-
αHis cells, we detected a significant reduction of H-Ec4-linker-G3 
proteins in virus particles as compared to unmodified H, or mono-
specific H-G3 and H-Ec4 (Figure 4h).
Taken together, bispecific MV variants with DARPin-based target-
ing domains containing different linkers were rescued and demon-
strated proper replication in two out of three analyzed cell lines. The 
infection by these viruses was highly toxic for both cancer cell lines 
tested, mandating the evaluation of this virus panel in an advanced 
in vivo setting.
Efficacy of bispecific MVs against disseminated orthotopic ovarian 
cancer
Oncolytic efficacy of the targeted MVs was tested in a model of 
disseminated orthotopic ovarian carcinoma.42 For this purpose, 
luciferase-expressing SK-OV-3 cells (SK-OV-3-luc) were intraperito-
neally (i.p.) injected into immuno-deficient nude mice. Since lucif-
erase signals in the peritoneum were readily detectable 2 dpi by 
in vivo imaging, the virotherapy treatment was started at this point. 
Subsequently, luciferase expression was monitored over time to 
determine tumor growth (Figure 5a).
Mock-treated control animals revealed a steady progression of 
the tumor burden. In a state of minimal residual disease on day 34, 
shown for representative mice treated with bispecific MV in com-
parison to untreated mock mice (Figure 5b), the tumor burden of 
all virus-treated animals was reduced by 76% (MV-Ec4-Pro9-G3) 
to 95% (MV-Ec4) as compared to the control group (Figure 5b,c). 
Interestingly, at least two MV, monospecific EpCAM-targeted 
MV-Ec4 and bispecific MV-Ec4-(G4S)2-G3, revealed a tendency for a 
higher oncolytic efficacy in vivo than MVNSe. This is remarkable since 
unmodified MVNSe is de facto also “targeted” to the tumor cells, which 
are the only cells expressing human CD46 in this in vivo model, since 
athymic nude mice are not susceptible to MV and do not express 
human CD46. MVs’ therapeutic efficacy became even more appar-
ent when analyzing the time to progression. Tumor growth pro-
gressed rapidly in mock-treated animals while it was significantly 
delayed in all MV-treated animals (Figure 5d).
However, most tumors relapsed and the mice had to be sacrificed. 
The sacrificed control animals had disseminated disease throughout 
the peritoneal cavity and showed signs of ascites. In contrast, the 
virus-treated animals did not develop ascites and there were fewer 
but larger tumors detectable (Supplementary Figure S4, arrows). 
Moreover, no alterations in the expression levels of the targeted 
receptors were detectable in dissociated tumor cells derived from 
representative explanted tumors (data not shown). Additionally, the 
cells could readily be reinfected with the respective viruses used for 
treatment (data not shown) indicating no treatment resistance in 
postentry steps. Thus, all recombinant MVs exhibited a significant 
oncolytic efficacy in a disseminated tumor model.
Figure 3 Receptor tropism of bispecific measles viruses (MVs). A panel 
of receptor-transgenic CHO cell lines (as indicated) including the 
parental CHO-K1 cells was infected with parental MVNSe, monospecific, 
or bispecific MVs (MOI = 0.3). Infected cultures were analyzed 48 hours 
after infection by fluorescence microscopy. Representative pictures are 
shown. Scale bar, 400 μm.
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Bispecific MVs are superior in targeting heterogeneous tumor cell 
populations
Having provided proof of principle for the oncolytic efficacy of 
bispecific MVs in vitro and in vivo, we aimed next at analyzing 
their potential for treating heterogeneous tumor cell populations. 
Two tumor cell lines (LN-308 and MCF-7) with distinct HER2 and 
EpCAM36 expression patterns (Table 1, Figure 6), were cocultivated 
and infected with the mono- or bispecific MVs. For better discrimi-
nation between the cell lines, LN-308 cells were genetically labeled 
with TurboFP635. Infection of these red-fluorescent LN-308red cells 
with GFP-expressing MVs resulted in yellow syncytia (due to mixed 
red and green fluorescence), in contrast to unmodified MCF-7 giv-
ing rise to green syncytia after infection (Supplementary Figure S5). 
Of note, the shape of the MV-induced syncytia is cell-specific, too. 
Infection of a mixed culture of LN-308red and MCF-7 with the vari-
ous viruses induced syncytia of different shapes and shades of yel-
low (red and green fluorescence), as both cell populations are fused 
(Figure 6a). The only exception was MV-Ec4 which induced only 
green syncytia (Figure 6a) matching the shape of syncytia formed 
by MCF-7 cells in the infected mono-culture (Supplementary Figure 
S5). This is in accordance with the inability of MV-Ec4 to infect iso-
lated LN-308red cells (Supplementary Figure S5).
Cytotoxicity of infection was subsequently determined with MTT 
assays on infected, isolated (Figure 6b,c), or mixed cultures (Figure 
6d) of unlabeled LN-308 and MCF-7 cells. These assays demon-
strated that both monospecific MVs were cytotoxic for the respec-
tive cell line (Figure 6b,c), which expressed the targeted receptor at 
high levels, but not vice versa (Table 1). In either cell line, the most 
Figure 4 Cytolytic efficacy of bispecific measles viruses (MV) in vitro. (a,b) The human ovarian adenocarcinoma cell line SK-OV-3 (a) or the human 
colorectal adenocarcinoma cell line Caco-2 (b) were infected with parental MVNSe, monospecific, or bispecific MVs (MOI = 1) and their viability was 
determined at the indicated time points by MTT assay. Depicted is metabolic activity indicating viability relative to the mock infected control culture. 
Mean of three independent experiments each consisting of four replicates. Error bars indicate SD. (c–f) Multi-step growth analysis of recombinant MV 
on SK-OV-3 (c,e) or Caco-2 (d,f) cells after infection at an MOI of 0.03. Cell-associated (c,d) or released viruses (e,f) were titrated on Vero-αHis cells. Mean 
of three independent experiments, error bars indicate standard deviation. (g) Impact of DARPins on MV infection. SK-OV-3 cells were incubated with 
recombinant DARPin-Fc proteins and infected with nontargeted MVNSe at an MOI of 0.03. Cell-associated titers were determined 48 hours after infection. 
(h) Immunoblot analysis of purified virus particles from supernatants of infected Vero-αHis cells. Proteins separated on 10% SDS-PA-gel were detected 
by antibodies directed against the indicated viral proteins. H, hemagglutinin; H-D, hemagglutinin fused with designed ankyrin repeat protein(s); MV, 
measles virus; N, nucleocapsid protein.
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efficient bispecific MVs were at least as effective in cell killing as the 
respective monospecific MV targeting the appropriate receptor 
(Figure 6b,c). On MCF-7, the bispecific viruses were even superior to 
MV-Ec4 in tumor cell killing (Figure 6c). Interestingly, linker variation 
again enhanced the oncolytic efficacy of the bispecific candidates. 
On LN-308, MV-Ec4-αHelix2-G3 and MV-Ec4-Pro9-G3 were more 
cytotoxic than the prototypic MV-Ec4-G3 virus (Figure 6b). Seventy-
two hours after infection, the cytotoxicity of MV-Ec4-Pro9-G3 was 
enhanced, whereas that of MV-Ec4-αHelix2-G3 was comparable to 
that of MV-Ec4-G3 on MCF-7 cells (Figure 6c).
The full potential of the bispecific viruses became evident when 
infecting the coculture of both cell lines. All bispecific viruses 
revealed superior oncolytic efficacy (MV-Ec4-G3: 58%, MV-Ec4-
αHelix2-G3: 34%, MV-Ec4-Pro9-G3: 30% residual viability 72 hours 
after infection) compared to either monospecific virus (MV-G3: 78%, 
MV-Ec4: 76% residual viability 72 hours after infection) (Figure 6d). 
Moreover, the optimized constructs MV-Ec4-αHelix2-G3 and 
MV-Ec4-Pro9-G3 exhibited an almost twofold enhanced cytotoxic 
effect compared to the prototype virus MV-Ec4-G3 at this time 
point. Noteworthy, the viability was further declining in infected 
cultures at the end of the observation period, indicating the poten-
tial of the bispecific MVs for eradication of the mixed culture over 
prolonged infection periods.
DISCUSSION
The general suitability of DARPins as targeting domains for onco-
lytic MVs and a prototypic MV targeted against two different anti-
gens have been presented in our previous studies.36 Here, our data 
reveal the advantages of optimized oncolytic viruses, which are 
targeted to two different tumor markers, simultaneously. Thereby, 
Figure 5 Therapeutic efficacy of bispecific measles viruses (MV) in disseminated orthotopic ovarian cancer. (a) Schematic depiction of the treatment 
schedule in a human xenograft tumor model in athymic mice implanted i.p. with SK-OV-3-luc cells. Two days thereafter, mice were injected i.p. four 
times as indicated with viruses (2 × 106 TCID50/injection) or control. n = 7–8. To monitor tumor burden, mice were imaged for luciferase activity starting 
on day 2, twice a week from day 9 to 27, then once a week until day 34 and finally once every 2 weeks, thereafter. (b) Representative IVIS images of 
mock-treated or bispecific MV-treated mice at the start of the treatment cycle (d2) and at the point of minimal residual disease (d34). (c) Mean luciferase 
activities over the course of the experiment in the differently treated groups (n = 7–8). Error bars, SD. (d) Tumor progression as defined by doubling 
of the initial luciferase signal, or when animals had to be sacrificed due to critical tumor location. Logrank test, **P < 0.01 (mock versus (G4S)2-treated).
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enhancement of the bispecific targeted viruses’ fusion activity was 
one of the aims of the presented studies. For this purpose, the linker 
peptide connecting both targeting entities was varied to study its 
impact on glycoprotein-induced fusion, a major determinant of 
recombinant MVs’ cytotoxicity.43 Fusion helper function of bispecific 
MV-H was best, when medium-sized linkers were used, irrespective 
of their flexibility. Bispecific oncolytic MVs replicated to identical 
titers as the monospecific viruses or parental MVNSe in two out of 
three tested cell lines, and revealed the expected conserved speci-
ficity. All viruses showed oncolytic activity comparable to monospe-
cific MVs and parental MVNSe in in vitro cultures and in vivo tumor 
models. Thereby, no hint for attenuation by the presence of two 
linked DARPins in series on the virus coat was found. Finally, the 
advantage of bispecific over monospecific viruses became evident 
in a mixed tumor cell model, representative for tumor heterogene-
ity found in vivo.
The connection of two DARPins turned out as an important param-
eter for their function as targeting domain for tumor-targeted onco-
lytic viruses. When used for oncolytic MVs, the linker determines the 
spatial orientation and flexibility of the two DARPins with respect to 
each other. In our study, accessibility of the individual DARPins for 
receptor binding most likely depends on the linker that may or may 
not cause steric hindrance on the individual DARPin domains. For 
example, optimal efficacy for delivering siRNA coupled to EpCAM-
specific DARPins was reached if they were arranged such that they 
could simultaneously bind to two EpCAM epitopes at the tumor cell 
surface.44 In our study, linkers of intermediate length revealed best 
biological function in vitro regardless of flexibility. Thus, the distance 
of both binding domains seems to be a critical parameter for this 
application.
As DARPins have a highly stable fold,45 distance effects likely influ-
ence their spatial orientation, or the transmission of the molecular 
force exerted by ligand binding to the globular head of H. If the linker 
is too short, the DARPins might mutually block binding to their des-
ignated targets. If the linker is too long, the distance between cel-
lular and virus particle membranes might be too long for efficient 
induction of fusion. This distance has been demonstrated to be a 
critical determinant for MV glycoprotein-mediated fusion.46 Thus, 
the intermediate linker size most likely reflects the best suited com-
promise. At least receptor binding was found to be conserved when 
analyzing the binding of Fc-tagged recombinant binding domains 
to the respective target cells, even though the Fc part was fused at 
the C-terminus of the DARPins and is thus not directly comparable 
to the fusion of H at the N-terminus of the DARPins.
The only exception found was the cassette with the Pro9-linker, 
but one could speculate about interference of the stiff linker with 
Figure 6 Cytolytic efficacy of bispecific measles viruses (MVs) for heterogeneous tumor populations in vitro. (a) LN-308red and MCF-7 were cocultivated 
at approximately 1:1 ratio and infected by parental MVNSe, monospecific, or bispecific MVs at an MOI of 0.1, respectively. Representative pictures after 
fluorescence microscopy 40 hours after infection are depicted. Scale bar, 400 μm. (b–d) LN-308 (b), MCF-7 (c) or both cell lines in coculture (d) were 
infected with parental MVNSe, monospecific, or bispecific MVs (MOI = 1) and their viability was determined at indicated time points by MTT assay. 
Depicted is metabolic activity indicating viability relative to the mock infected control culture. Mean of three independent experiments each consisting 
of four replicates. Error bars, SD. n-way analysis of variance with factors virus group (mono versus bispecific), virus (nested in virus group), and time 
(hours postinfection); ***P < 0.001.
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protein folding when expressed as Fc fusion. This recombinant pro-
tein was expressed at by far lowest levels as N-terminal fusion pro-
teins to the Fc-tag after transfection of 293T cells. Thus, degradation 
seems to be induced under these conditions, which can be most 
easily explained by co- or post-translationally misfolded protein. In 
contrast, expression of the targeting cassette with the Pro9-linker 
when C-terminally fused to H seemed not to be impaired. Therefore, 
it is consistent with this observation that all viruses had high onco-
lytic efficacy.
For cell fusion and the fusion helper function of H, linker flexibility 
seems to play just a secondary role for. Only the extent of receptor 
usage changed from a HER2-dominated targeting for (G4S)x-linkers 
to a more balanced pattern for more rigid linkers such as αHelix2 
and Pro9, while hinge-encompassing linkers did worse. Fusion is 
triggered by H, whose globular head binds to a receptor, leading 
to subsequent conformational changes that are transmitting the 
activation signal to the fusion protein.47 Since the EpCAM-binding 
DARPin is directly connected to H in our constructs, transmission 
of molecular forces caused by the DARPin-mediated binding of 
the globular head of H to EpCAM should not be modulated by the 
linker peptide sequence. Our data indicate an enhanced EpCAM-
dependent fusion activity when more rigid linkers are used, likely 
due to an enhanced spatial separation of both DARPin units. In con-
trast, binding of the outer DARPin unit is transmitted to the H head 
irrespective of the linker flexibility.
When these more rigid linkers of intermediate length were intro-
duced into recombinant MVs, the resulting viruses revealed a con-
served replication pattern in Vero-αHis cells as compared to the 
EpCAM-targeted MV, while their receptor tropism was solely deter-
mined by the binding specificity of the displayed DARPins. Thereby, 
the phenotype of the bispecific targeting units, as expected, reflects 
the behavior of each of the monospecifically targeted MVs using 
monospecific targeting domains,33–36 or the prototypic bispecific 
MV.36 The oncolytic potency of the newly generated bispecific MVs 
correlated well with the fusion helper activity of the respective 
recombinant H proteins. Such correlation has been described before 
for MV strains “naturally” differing in their fusion activity43,48 as well 
as for monospecific targeted oncolytic MVs.36 Fusion-helper activity 
and cytotoxicity are dependent on receptor density, for both non-
targeted30,49 and monospecifically targeted viruses.36,50 Thus, it was 
not surprising to observe such a correlation for the bispecific MVs 
as well.
Surprising differences became, however, evident for the replica-
tion of bispecific MVs on a certain tumor cell line. In SK-OV-3 cells, 
cell-associated titers of bispecific MVs were reduced compared to 
other MVs. SK-OV-3 cells express both receptors in high density at 
the cell surface36 and are killed by the bispecific viruses more effi-
ciently than by either monospecific virus. Impaired productive rep-
lication of bispecific MVs seems to be a specific feature of SK-OV-3 
cells, since the pattern of replication of bispecific viruses in Caco-2 
and Vero-αHis cells followed that of monospecific or nontargeted 
viruses. Enhanced cytotoxicity as potential cause of impaired rep-
lication in SK-OV-3 might curb virus titers due to premature cell 
killing, as observed before,43 but nontargeted MVNSe was at least as 
cytotoxic, and replicated better. In addition, toxicity of bispecific 
MVs for Caco-2 cells was found to be enhanced compared to solely 
HER2-targeted MV, but replication was at least as good. Thus, cyto-
toxicity seems not to be the differentiating factor, here.
A self-contained effect of the bispecific DARPin units on cell phys-
iology through targeted receptor signaling, like recently described 
for other bispecific HER2-binding DARPins,51 could be excluded by 
incubation of SK-OV-3 cells with bispecific DARPin-linker-DARPin-Fc 
proteins and subsequent infection with MVNSe. Cell-specific impair-
ment of virus assembly in SK-OV-3 cells and reduced virus release 
due to the high receptor expression levels in SK-OV-3 cells may be 
alternative explanations for reduced infectivity, as some cell- specific 
features of MV replication affecting titers have been previously 
described also for clinical grade vector production.52
The only difference between bi- and monospecific MV was the 
reduced incorporation of H-Ec4-linker-G3 proteins into recombi-
nant MV particles. Obviously, the amount of recombinant H on the 
respective virus particles was sufficient for replication on two other 
cell lines and for significant cytotoxicity in all five cell lines tested. 
Nevertheless, high-affinity interaction between the displayed 
DARPin domain and the HER2 receptor in the endoplasmic reticu-
lum of the virus-infected cell may interfere with virus spread espe-
cially on the SKOV cells, which have a very high density of the HER2 
receptor. However, elucidating this issue may be a matter of future 
experiments.
In the model of peritoneal carcinomatosis, all viruses, including 
MVNSe, controlled tumor burden to a similar extent. If at all, mono-
specific MV-Ec4 and bispecific MV-Ec4-(G4S)2-G3 performed best, 
even doing slightly better than nontargeted virus. Interestingly, 
in vitro they had been least cytotoxic. In a comparable experiment, 
treatment with nontargeted recombinant MV (closely reflecting 
MVNSe used in this study) resulted in similar level of residual tumor 
burden as evaluated by tumor cells’ luciferase activity in the state 
of minimal residual disease.53 Remarkably, in our experiment, virus 
treatment resulted in remission of the tumors below the starting 
volume, whereas tumors in the parallel study only went into stasis.53 
Thus, therapeutic efficacy in our experiments was clearly within the 
expected range for an oncolytic virus. Interestingly, oncolytic MVs 
seem to be superior to other experimental treatment modalities 
previously tested in this tumor model. When HER2-affibodies cou-
pled to a bacterial toxin were administered, the exponential tumor 
growth rate was attenuated, but no remission of the tumor burden 
was observed.54
Moreover, our oncolytic MVs changed the tumor phenotype 
in this in vivo model from a poly-focal to an oligo-focal pattern 
going along with absence of ascites. The latter had also been 
previously observed with nontargeted MV.42 Also, in these experi-
ments, only few and small residual tumors were isolated at day 
80. Most likely, only a small fraction of the initially injected tumor 
cells survived virus treatment, which then relapsed to few large 
tumors. It  is tempting to speculate that these remaining tumor 
nests can be better controlled by using an extended treatment 
schedule. Indeed, a significantly prolonged schedule (16 injec-
tions over 6 weeks of treatment) and 14 times higher total dose 
of virus (1.6 × 108 pfu) can result in smaller tumor loads on day 80 
post-treatment.42 However, with (targeted) therapies being pres-
ent over a longer period of time, selective pressure for tumor cells 
escaping the therapy increases, as already documented in vitro for 
oncolytic MV.36 For trastuzumab targeting HER2, compensatory 
activation of different pathways, altered intracellular signaling6,55,56 
or receptor downregulation57 have been described.
To assess the potential for resistance against our viruses 
described here, we isolated representative tumors 17–32 weeks 
after treatment. No signs for resistant tumor cells explaining the 
relapse could be identified including target receptor expression 
und MV-susceptibility. However, the postulated advantage of bispe-
cific targeted MVs with respect to resistance development cannot 
be properly documented in this setting given (i) the absence of 
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virus in isolated tumors that might have induced resistance and 
(ii) lack of heterogeneity in the orthotopic tumor model used here. 
Nevertheless, the picture might change, when the selective pres-
sure is increased by using more treatment cycles or heterogenic 
tumors are established in vivo, thus enforcing resistance develop-
ment to mono-targeted therapies.
Indeed, in an in vitro model mimicking tumor heterogeneity, all 
bispecific MVs were superior to monospecific viruses in eradicating 
mixed tumor cells. Again, higher rigidity of the linker improved the 
efficacy (MV-Ec4-αHelix2-G3 and MV-Ec4-Pro9-G3). These in vitro 
data indicate the power of simultaneous targeting of two different 
receptors, especially when treating heterogeneous cell populations. 
Combination of two monospecific MV differs from simultaneous 
targeting by bispecific MV, since the latter have an inherent bispeci-
ficity of each single particle. Bispecificity of the targeted agents is 
thus continuously present in any infected cell, and thereby, a single 
virus should be able to spread throughout heterogeneous tumor 
tissue, whereas two simultaneously applied viruses may encounter 
regions that cannot be crossed by one of the viruses preventing 
effective spread and therapy.
Moreover, two completely independent oncogenic pathways 
can simultaneously be targeted using bispecific MVs. Both, HER2 
and EpCAM are associated with bad prognosis for the patient.3,16 
Combined targeting of cells expressing either one or two markers 
should therefore extend the potential of MV to kill critical tumor 
cell populations with different roles in uncontrolled tumor growth 
such as tumor evolution and metastasis. Whether the high in vivo 
efficacy of EpCAM-targeted MV-Ec4 can be attributed to the target-
ing of cancer stem cells, or not, remains to be elucidated. By careful 
choice of the targeted pathways, development of resistance might 
potentially also be suppressed.
Taken together, bispecific MVs targeted by two combined 
DARPins are a novel and unique type of virotherapeutic antitu-
moral agent. They harbor an intrinsic and robust bispecificity that 
allows them to replicate in an extended proportion of heteroge-
neous tumor cell populations. In addition, they are independent of 
a singular target structure; thereby the chance for easy resistance 
development should be suppressed. Furthermore, using the highly 
versatile DARPin technology,37 specificity of the viruses, in principle, 
can be directed to almost any target of choice, including critical 
antigens on cancer stem cells and pathways critical for tumor cell 
survival and metastasis.
MATeRIAlS AND MeTHODS
Cells
293T (CRL-11268), CHO-K1 (CCL-61), SK-OV-3 (HTB-77), Caco-2 (HTB-37), and 
MCF-7 (HTB-22) cells were purchased from ATCC (Manassas, VA) and grown 
in media recommended by ATCC at 37 °C in a humidified atmosphere con-
taining 6% CO2 for no longer than 6 months of culture after thawing of the 
original stock. Vero-αHis,33 CHO-hSLAM,26 CHO-CD46 (ref. 58), CHO-nectin4 
(ref. 59), CHO-HER2 (ref. 60), CHO-EpCAM,36,61 and LN-308 (ref. 62) cells and 
their maintenance have been described. SK-OV-3-luc and LN-308red were 
generated by transduction of SK-OV-3 (MOI 0.5) or LN-308 (MOI 50) cells, 
respectively, with an HIV-1 derived lentiviral vector system pseudotyped 
with VSV-G63 encoding firefly luciferase or the TurboFP635 gene (pS-TFP635-
W64). SK-OV-3-luc single cell clones were subsequently analyzed for lucifer-
ase and HER2/neu expression. One clone with high luciferase expression and 
unaltered HER2/neu expression was used for further experiments. LN-308red 
cells were used as bulk culture.
Plasmids
For cloning bispecific H variants, a modular system was generated, where 
the linker connecting both DARPins is easily exchangeable via XmaI/BstBI 
restriction sites. On the basis of the plasmid pCR2.1-Ec4-G3 (ref. 36), the 
αEpCAM-DARPin coding sequence was elongated by polymerase chain 
reaction (PCR) (Expand High FidelityPLUS PCR System, Roche Diagnostics, 
Mannheim, Germany) to introduce a SfiI site to the 5’ end and adjacent 
XmaI/BstBI sites in 3’. PCR products were directly ligated into pCR2.1-
TOPO (TOPO-TA cloning kit, Life Technologies, Darmstadt, Germany) and 
sequenced (Eurofins MWG Operon, Ebersberg, Germany). The resulting 
SfiI-Ec4-BstBI fragment was inserted into pCR2.1-Ec4-G3 via SfiI/BstBI (NEB, 
Frankfurt a.M., Germany) to generate pCR2.1-Ec4-X/B-G3 with a single Gly-
Ser encoding linker sequence between the adjacent XmaI/BstBI restriction 
sites. The different linker peptide-encoding sequences were subsequently 
ligated into pCR2.1-Ec4-X/B-G3 via XmaI/BstBI (NEB) using preannealed 
(2 minutes 95°C, then slow cool-down to RT) synthetic oligonucleotides 
(Eurofins MWG Operon) with sticky ends. The different bispecific DARPin-
linker-DARPin cassettes were then inserted into pCG-HmutXαCD20 (ref. 65) 
via SfiI/NotI (NEB) to yield expression plasmids for bispecifically retargeted 
H (pCG-Hmut-Ec4-X/B-G3, pCG-Hmut-Ec4-αHelix2-G3, pCG-Hmut-Ec4-
αHelix2-hi-G3, pCG-Hmut-Ec4-αHelix4-G3, pCG-Hmut-Ec4-αHelix4-hi-G3, 
pCG-Hmut-Ec4-(G4S)1-G3, pCG-Hmut-Ec4-(G4S)2-G3, pCG-Hmut-Ec4-(G4S)3-
G3, pCG-Hmut-Ec4-(G4S)4-G3, pCG-Hmut-Ec4-Pro9-G3, pCG-Hmut-Ec4-
Pro9-hi-G3, pCG-Hmut-Ec4-Pro18-G3, and pCG-Hmut-Ec4-Pro18-hi-G3). The 
H-DARPin-linker-DARPin-encoding genes were transferred via PacI/SpeI 
into plasmid p(+)PolII-MVNSe-GFP(N)
36 to yield p(+)PolII-MVNSe-GFP(N)-Ec4-
(G4S)2-G3, p(+)PolII-MVNSe-GFP(N)-Ec4-αHelix2-G3, and p(+)PolII-MVNSe-
GFP(N)-Ec4-Pro9-G3. As the cassettes in pCG-Hmut-Ec4-αHelix2-G3 and 
pCG-Hmut-Ec4-Pro9-G3 were not conforming to the ‘rule of six’, their ter-
minal His6-tag was elongated before subcloning by an additional His via 
NotI/SpeI (NEB) using appropriate synthetic oligonucleotides (Eurofins MWG 
Operon). Detailed sequences of primers, PCR programs and oligonucle-
otides are available upon request. For the expression of DARPin-Fc proteins, 
different DARPin cassettes were excised by SfiI/NotI (NEB) and fused in-frame 
to a human IgG1-Fc-tag in the plasmid phuFc-(SfiI-NotI)66 to yield phuFc-G3, 
phuFc-Ec4, phuFc-Ec4-G3, phuFc-Ec4-αHelix2-G3, and phuFc-Ec4-Pro9-G3.
DARPin-Fc expression and purification
DARPin-Fc proteins were expressed and purified as described before.66 In 
short, phuFc-derived plasmids were transfected into 293T cells and subse-
quently medium was replaced with serum-free PANSERIN 293A (Pan-Biotech, 
Aidenbach, Germany). 48 and 72 hours post-transfection, medium was 
cleaned using a 0.22-µm filter and pooled. Fc-tagged proteins were purified 
by a Sartobind Protein A column (Sartorius, Göttingen, Germany) on a high 
performance liquid chromatography (HPLC) system (Bioline, Knauer, Berlin, 
Germany) according to the manufacturer’s instructions. Purity was analyzed by 
Coomassie blue staining (GelCode Blue Safe Protein Stain, Thermo Scientific, 
Dreieich, Germany) after separation using sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE). Protein concentration was analyzed by 
the absorption at 280 nm (NanoDrop, Thermo Scientific).
Viruses
For rescue of recombinant MV, the previously described PolII rescue system67 
was used with modifications. In short, the plasmids encoding recombinant MV 
genomes were cotransfected with expression plasmids pCA-MV-N, pCA-MV-P, 
and pCA-MV-L into 293T cells using Lipofectamine 2000 (Life Technologies). 
Two days after transfection, transfected 293T cells were overlaid onto 50% 
confluent Vero-αHis cells allowing rescue of retargeted viruses. The viruses 
were propagated in Vero-αHis cells and titers were determined by 50% tissue 
culture infective dose (TCID50) titration on Vero-αHis cells.
68,69
Virus particle purification
Vero-αHis cells were seeded in 10 cm dishes and infected with respective 
MV (multiplicity of infection (MOI) = 0.03). The culture supernatants were 
collected 2 days after infection, clarified and pelleted in an SW28 rotor 
(25,000 rpm, 2.5 hours) through 20% sucrose onto a 60% sucrose cushion in 
STE buffer (10 mmol/l Tris (pH 8.0), 100 mmol/l NaCl, and 1 mmol/l ethylene 
diamine tetraacetic acid (EDTA) (pH 8.0)). Purified viral particles were pel-
leted in an SW41 rotor (35,000 rpm, 1.5 hours) through 20% sucrose, resus-
pended in RIPA lysis buffer, and subjected to immunoblot analysis.
Transfection of mammalian cells
For expression analysis, the different pCG-H expression plasmids were 
transfected into 293T cells using lipofectamine-2000 (Life Technologies). 
8 × 105 293T cells were seeded in six-well plates (Nunc Delta Surface; Thermo 
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Scientific) 1 day prior to transfection. For transfection, 5 μg DNA were mixed 
with 12.5 μl lipofectamine-2000 in OptiMEM and transfected according 
to the manufacturer’s protocol. The transfection mix was changed after 
4 hours to culture medium. 48 to 72 hours post-transfection, transfected 
cells were used for further analysis. Transient transfection to assess fusion 
helper function was done by seeding 3.5 × 105 CHO-HER2, CHO-EpCAM, or 
CHO-K1 cells plated in 12-well plates (Nunc Delta Surface) 1 day prior to 
transfection. 1 μg of pCG-F70 and 1 μg of a plasmid encoding one H variant 
were mixed by vortexing with 3 μl FuGENE HD Transfection Reagent (Roche 
Diagnostics) in OptiMEM and incubated for 15 minutes at room tempera-
ture. Transfection mix was added drop-wise to cells without exchanging the 
medium afterwards.
Infection of mammalian cells
Cells were seeded in an appropriate plate (Nunc Delta Surface) and infected 
1 to 4 hours after seeding when reaching 50–70% confluence by a defined 
MOI via simple addition of virus suspension. Infected cells were cultivated 
and analyzed 48–72 hours after infection at the peak of viral infection. For 
analysis of receptor specificity, 3 × 105 of respective receptor-transgenic CHO 
cells were seeded in six-well plates and infected at an MOI of 0.3. To assess 
tumor heterogeneity, 1 × 105 LN-308red and 2 × 10
5 MCF-7 were seeded in 
12-well plates or 2 × 105 of each cell line separately, and infected at an MOI 
of 0.1.
Immunoblotting
Forty-eight hours post-transfection or infection with viruses at an MOI of 
0.1, cells were lysed in radio immunoprecipitation assay (RIPA) lysis buffer 
(50 mmol/l Tris, 150 nmol/l NaCl, 1% NP40 (w/v), 0.5% sodiumdesoxycho-
late (w/v), 0.1% SDS (w/v), pH 8.0 + Protease Inhibitor Cocktail Complete 
(Roche Diagnostics)). Lysates were denatured in an equal volume of urea 
buffer (200 mmol/l Tris-HCl (pH 6.8), 8 mol/l urea, 5% SDS (w/v), 0.1 mmol/l 
EDTA, 0.03% bromophenol blue (w/v), 1.5% DTT (w/v)) for 10 minutes at 
95 °C and separated by SDS-PAGE (Bio-Rad, München, Germany). Proteins 
were transferred to a polyvinylidene difluoride membrane (Hybond-P; GE 
Healthcare, München, Germany) by the semi-dry method (TransBlot SD; Bio-
Rad) and blocked by 5% milk powder (Roth, Karlsruhe, Germany) in TBS-T 
(50 mmol/l Tris-HCl (pH 7.4), 150 mmol/l NaCl, H2O, 0.1% Tween 20 (v/v)) for 
a least 1 hour at room temperature. Proteins were detected using as primary 
antibodies αMV-H (1:20,000),71 αMV-N (clone ab23974; 1:25,000; Abcam, 
Cambridge, UK) or α-β-actin (clone AC-15; 1:5,000; Abcam) over-night at 
4 °C, and donkey-α-rabbit-HRP sera (1:10,000; Rockland, Limerick, PA) or 
rabbit-α-mouse-HRP sera (1:10,000; Life Technologies) as secondary Abs for 
at least 45 minutes at room temperature. Finally, membranes were analyzed 
using ECL+ (GE Healthcare) detection reagent.
Flow cytometry analysis
Expression of H-DARPin-linker-DARPin proteins was analyzed using directly 
fluorescently-labeled αHis6-PE (clone GG11-8F3.5.1; 1:11; Miltenyi Biotec, 
Bergisch Gladbach, Germany). Surface expression of HER2/neu, EpCAM, or 
CD46 was detected using fluorescence-labeled mAbs αHER2-PE (clone Neu 
24.7; 1:80; BD Bioscience, Heidelberg, Germany), αEpCAM-PE (clone HEA-
125; 1:100; Miltenyi Biotec), or αCD46-AlexaFluor700 (clone MEM-258; 1:100; 
EXBIO, Vestec, Czech Republic), respectively. Viability of cells was analyzed 
using viability dye (Fixable Viability Dye eFluor 450; 1:1,000; eBioscience, 
Frankfurt a.M., Germany). Tumor cells were stained either directly after cell 
isolation or after isolated cells formed a confluent layer in cell culture. To 
analyze DARPin-Fc binding, 2 × 105 cells were incubated with the respective 
concentration of DARPin-Fc for 1 hour and stained with α-human-IgG1-Fcγ-
AlexaFluor647 (Jackson ImmunoResearch, Suffolk, UK; 1:100) antibody for 
45 minutes. For determining the ratio for an equal number of LN-308 and 
MCF-7 in coculture, LN-308 were labeled by CFSE, mixed with unstained 
MCF-7, and analyzed by flow cytometry. For CFSE labeling, cells were incu-
bated with CFSE for 10 minutes at 37 °C in PBS containing 10% FCS. The reac-
tion was then stopped with five volumes of cold PBS on ice for 5 minutes and 
cells were washed once with culture medium. Flow cytometry analyses were 
made using a LSRII flow cytometer (BD Bioscience).
Fusion assay
Four hours after transfection of respective cell lines with expression plas-
mids encoding the H variants to be analyzed together with F, 200 μmol/l 
fusion inhibitor peptide (FIP72; BACHEM, Bubendorf, Switzerland) was added 
and cells were incubated for 24 hours. Fusion was started by removal of FIP 
and cultures were fixed with 10% paraformaldehyde in PBS after formation 
of syncytia. Fixed cultures were subjected to microscopic analysis and the 
number of nuclei per syncytium was determined for 25 independent syncy-
tia for each retargeted H variant.
Virus growth kinetics
2 × 105 SK-OV-3, Vero-αHis, or 3 × 105 Caco-2 cells were seeded in 12-well 
plates (Nunc Delta Surface). Cells were infected at an MOI of 0.03 in a total 
of 1 ml medium. At the indicated time points, supernatants were clarified by 
centrifugation and stored in aliquots at −80 °C. Infected cells were scraped 
into 1 ml OptiMEM and subjected to a freeze-thaw cycle. After thawing, 
supernatants containing released particles were also clarified by centrifuga-
tion and stored in aliquots at −80 °C. Cell-associated virus titers and titers 
of virus in supernatants were determined by TCID50 titration. To analyze the 
effect of DARPins on MV replication, 10 µmol/l of the respective DARPin-Fc 
was added to the SK-OV-3 cells twice: once during the infection and 24 hours 
after infection. Viral titers were analyzed 48 hours after infection.
Cytotoxicity assay
1 × 104 cells were seeded in in flat-bottom 96-well plates (Nunc Delta 
Surface) and infected with recombinant MV (MOI = 1), or left uninfected 
(mock), for each sample and time-point in quadruplicates. Viability of the 
cells after infection was determined using MTT assay (Cell Proliferation Kit 
I; Roche Diagnostics) according to manufacturer´s instructions. 24, 48, 72, 
96, or 168 hours after infection, cells were incubated with MTT solution for 4 
hours. Then, solubilization solution was added. Following overnight incuba-
tion, formation of formazan dye was quantified by 570 nm using an ELISA 
reader (Multiskan RC, Thermo Labsystems).
Animal experiments
Experimental mouse work was carried out in compliance with the regula-
tions of the German animal protection law. To evaluate the oncolytic efficacy 
against orthotopic tumors, 5 × 106 SK-OV-3-luc cells were intraperitoneally 
(i.p.) injected into 6- to 12-week-old female Hsd:Athymic Nude-Foxn1nu mice 
(Harlan, Rossdorf, Germany). The course of tumor development was moni-
tored by in vivo imaging (IVIS Spectrum; Perkin Elmer, Rodgau, Germany) 
at indicated time points by detecting bioluminescence 8 minutes after i.p. 
injection of 150 μg D-Luciferin (Perkin Elmer) per gm body weight. Two 
days after injection of tumor cells, mice were assigned into groups accord-
ing to luciferase signal intensities ensuring an even tumor burden in each 
group. Animals were euthanized when the mice lost more than 20% of body 
weight or showed symptoms of tumor related illness like ascites or cachexia. 
Representative tumors were prepared from sacrificed mice and tumor cells 
were isolated using GentleMACS (Miltenyi Biotec). In short, the tumor mass 
was cut into small pieces, 120 U/ml Collagenase I (Sigma) were added, and 
the tumor suspension was transferred to a “C-tube” (Miltenyi Biotec). After 
processing by the GentleMACS automat employing the program “m_impTu-
mor_02”, the suspensions were incubated for 1 hour at 37 °C and 180 rpm. 
Subsequently, a further GentleMACS processing step with “m_impTu-
mor_03” followed. The cell suspension was afterwards filtered using a 70 μm 
cell strainer (ThermoFisher Scientific). Cells were collected by centrifugation 
(300 g, 5 minutes, 4 °C), resuspended in culture medium, and cultivated for 
3–7 days to 90–100% confluence before analysis.
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